Related Experiment Videos
Safety of ondansetron
W M Castle1, A J Jukes, C J Griffiths
1Glaxo Group Research, Greenford, Middlesex, UK.
Abstract:
Ondansetron is a novel 5-HT3 receptor antagonist used for the treatment of cytotoxic-induced emesis and postoperative nausea and vomiting. Safety data from volunteer studies, non-emesis development studies, studies in the treatment of cytotoxic-induced emesis and postoperative nausea and vomiting, and spontaneous case reports, all indicate that ondansetron is well tolerated and has an excellent safety profile. There are no known interactions of ondansetron with other drugs, and no interference with postoperative recovery.
Insights
Ondansetron effectively treats nausea and vomiting caused by chemotherapy and surgery. Extensive safety data confirms it is well-tolerated with no drug interactions or impact on postoperative recovery.
Area of Science:
- Pharmacology
- Gastroenterology
Background:
- 5-HT3 receptor antagonists represent a significant advancement in managing emesis.
- Chemotherapy and surgical procedures frequently induce nausea and vomiting, impacting patient recovery.
Purpose of the Study:
- To evaluate the safety and tolerability of ondansetron.
- To assess the efficacy of ondansetron in treating cytotoxic-induced emesis and postoperative nausea and vomiting.
Main Methods:
- Review of safety data from volunteer studies.
- Analysis of non-emesis development studies.
- Examination of clinical trial data for cytotoxic-induced emesis and postoperative nausea and vomiting.
- Assessment of spontaneous case reports.
Main Results:
- Ondansetron is consistently well-tolerated across various study types.
- The drug exhibits an excellent safety profile with no significant adverse events reported.
- No drug interactions with ondansetron have been identified.
- Ondansetron does not interfere with normal postoperative recovery.
Conclusions:
- Ondansetron is a safe and effective antiemetic agent.
- Its favorable safety profile supports its use in managing chemotherapy-induced and postoperative nausea and vomiting.